MDSpire - Takeaway
FDA & Government News

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Share

  • 1

    FDA decisions expected in April across multiple specialties.

  • 2

    GTx-104 targets aneurysmal subarachnoid hemorrhage.

  • 3

    AXS-05 aims to treat Alzheimer's agitation.

  • 4

    Sparsentan is for focal segmental glomerulosclerosis.

  • 5

    Teplizumab seeks to delay type 1 diabetes progression.

  • 6

    DOR/ISL is an investigational treatment for HIV-

  • 7

    Various PDUFA target action dates throughout April.

Original Source(s)

FDA Monthly Preview: Key April Decisions to Watch

  • by Kathryn Wighton

  • March 31, 2026

Related Content

Meat Intake, APOE Status Linked to Cognitive Aging

Long-term cohort data suggest genotype-specific associations with cognition, not dementia interaction

A Two-Biomarker Signal for Alzheimer’s Disease

Dual plasma biomarkers may improve identification of established Alzheimer’s disease and signal faster decline

Surgical Approaches Evolve in Tremor Syndromes

Evidence review highlights expanding role of neuromodulation and lesioning, with differences across tremor types